News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms 

Vertex Pharmaceuticals
Statistically Significant Results From Vertex VX-548 for Acute Pain
Vertex Pharmaceuticals (VRTX) announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery.

Treatment with an initial dose of 100 mg followed by 50 mg . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.